Epigenetics of glioblastoma multiforme: From molecular mechanisms to therapeutic approaches

Patel, 2019, Global, regional, and national burden of brain and other CNS cancer, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016, Lancet Neurol., 18, 376, 10.1016/S1474-4422(18)30468-X Laug, 2018, A glial blueprint for gliomagenesis, Nat. Rev. Neurosci., 19, 393, 10.1038/s41583-018-0014-3 Wang, 2019, Deletion of the RNA regulator HuR in tumor-associated microglia and macrophages stimulates anti-tumor immunity and attenuates glioma growth, Glia, 67, 2424, 10.1002/glia.23696 Jiang, 2017, Glioblastoma cell malignancy and drug sensitivity are affected by the cell of origin, Cell Rep., 18, 977, 10.1016/j.celrep.2017.01.003 Ostrom, 2017, CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014, Neuro. Oncol., 19, v1, 10.1093/neuonc/nox158 Claus, 2015, Survival and low-grade glioma: the emergence of genetic information, Neurosurg. Focus, 38, E6, 10.3171/2014.10.FOCUS12367 Klughammer, 2018, The DNA methylation landscape of glioblastoma disease progression shows extensive heterogeneity in time and space, Nat. Med., 24, 1611, 10.1038/s41591-018-0156-x Chow, 2018, Imaging genetic heterogeneity in glioblastoma and other glial tumors: review of current methods and future directions, Am. J. Roentgenol., 210, 30, 10.2214/AJR.17.18754 Sturm, 2012, Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma, Cancer Cell, 22, 425, 10.1016/j.ccr.2012.08.024 Saleem, 2019, The TICking clock of EGFR therapy resistance in glioblastoma: target Independence or target Compensation, Drug Resist. Updat., 43, 29, 10.1016/j.drup.2019.04.002 Dabrowski, 2019, Global DNA methylation patterns in human gliomas and their interplay with other epigenetic modifications, Int. J. Mol. Sci., 20, 10.3390/ijms20143478 Li, 2017, Epigenetic mechanisms of glioblastoma, 43 Frank, 2009, Metastatic glioblastoma cells use common pathways via blood and lymphatic vessels - PubMed, Neurol. Neurochir. Pol., 43, 183 Rich, 2005, Gene expression profiling and genetic markers in glioblastoma survival, Cancer Res., 65, 4051, 10.1158/0008-5472.CAN-04-3936 Dong, 2019, Epigenetic modulation of metabolism in glioblastoma, Semin. Cancer Biol., 57, 45, 10.1016/j.semcancer.2018.09.002 Romani, 2018, Epigenetic targeting of glioblastoma, Front. Oncol., 8, 448, 10.3389/fonc.2018.00448 Lu, 2020, Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy, Mol. Cancer, 19, 1, 10.1186/s12943-020-01197-3 Topper, 2020, The emerging role of epigenetic therapeutics in immuno-oncology, Nat. Rev. Clin. Oncol., 17, 75, 10.1038/s41571-019-0266-5 Kelly, 2017, The promise of epigenetic therapy: reprogramming the cancer epigenome, Curr. Opin. Genet. Dev., 42, 68, 10.1016/j.gde.2017.03.015 Jones, 2007, The epigenomics of cancer, Cell, 128, 683, 10.1016/j.cell.2007.01.029 Kloosterhof, 2013, Molecular subtypes of glioma identified by genome-wide methylation profiling, Genes Chromosom, Cancer, 52, 665 Wick, 2018, Understanding and treating glioblastoma, Neurol. Clin., 36, 485, 10.1016/j.ncl.2018.04.006 Dawson, 2017, The cancer epigenome: Concepts, challenges, and therapeutic opportunities, Science (80-.), 355, 1147, 10.1126/science.aam7304 Roberti, 2019, Epigenetics in cancer therapy and nanomedicine, Clin. Epigenetics, 11, 1, 10.1186/s13148-019-0675-4 Cheng, 2019, Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials, Signal Transduct. Target. Ther., 4, 1, 10.1038/s41392-019-0095-0 Guruharsha, 2012, The Notch signalling system: recent insights into the complexity of a conserved pathway, Nat. Rev. Genet., 13, 654, 10.1038/nrg3272 Andersson, 2011, Notch signaling: simplicity in design, versatility in function, Development, 138, 3593, 10.1242/dev.063610 Yang, 2004, Notch activation induces apoptosis in neural progenitor cells through a p53-dependent pathway, Dev. Biol., 269, 81, 10.1016/j.ydbio.2004.01.014 Hori, 2013, Notch signaling at a glance, J. Cell. Sci., 126, 2135 Šestan, 1999, Contact-dependent inhibition of cortical neurite growth mediated by Notch signaling, Science (80-.), 286, 741, 10.1126/science.286.5440.741 Breunig, 2007, Notch regulates cell fate and dendrite morphology of newborn neurons in the postnatal dentate gyrus, Proc. Natl. Acad. Sci. U. S. A., 104, 20558, 10.1073/pnas.0710156104 Stump, 2002, Notch1 and its ligands Delta-like and Jagged are expressed and active in distinct cell populations in the postnatal mouse brain, Mech. Dev., 114, 153, 10.1016/S0925-4773(02)00043-6 Carlén, 2009, Forebrain ependymal cells are Notch-dependent and generate neuroblasts and astrocytes after stroke, Nat. Neurosci., 12, 259, 10.1038/nn.2268 Irvin, 2001, Expression patterns of Notch1, Notch2, and Notch3 suggest multiple functional roles for the Notch-DSL signaling system during brain development, J. Comp. Neurol., 436, 167, 10.1002/cne.1059 Murphy, 2008, Endothelial Notch4 signaling induces hallmarks of brain arteriovenous malformations in mice, Proc. Natl. Acad. Sci. U. S. A., 105, 10901, 10.1073/pnas.0802743105 Irvin, 2004, Patterns of Jagged1, Jagged2, Delta-Like 1 and delta-like 3 expression during late embryonic and postnatal brain development suggest multiple functional roles in progenitors and differentiated cells, J. Neurosci. Res., 75, 330, 10.1002/jnr.10843 Yoon, 2008, Mind bomb 1-Expressing intermediate progenitors generate notch signaling to maintain radial glial cells, Neuron, 58, 519, 10.1016/j.neuron.2008.03.018 Shutter, 2000, D114, a novel Notch ligand expressed in arterial endothelium, Genes Dev., 14, 1313, 10.1101/gad.14.11.1313 Alberi, 2011, Activity-Induced Notch Signaling in Neurons Requires Arc/Arg3.1 and Is Essential for Synaptic Plasticity in Hippocampal Networks, Neuron, 69, 437, 10.1016/j.neuron.2011.01.004 Lavado, 2010, Prox1 is required for granule cell maturation and intermediate progenitor maintenance during brain neurogenesis, PLoS Biol., 8, 43, 10.1371/journal.pbio.1000460 Miller, 2009, Cis-inhibition of notch by endogenous delta biases the outcome of lateral inhibition, Curr. Biol., 19, 1378, 10.1016/j.cub.2009.06.042 Del Álamo, 2011, Mechanism and significance of cis-inhibition in notch signalling, Curr. Biol., 21, 10.1016/j.cub.2010.10.034 LeBon, 2014, Fringe proteins modulate Notch-ligand cis and trans interactions to specify signaling states, Elife, 3 Kopan, 2009, The canonical notch signaling pathway: unfolding the activation mechanism, Cell, 137, 216, 10.1016/j.cell.2009.03.045 Jarriault, 1995, Signalling downstream of activated mammalian Notch, Nature, 377, 355, 10.1038/377355a0 Iso, 2001, HERP, a New Primary Target of Notch Regulated by Ligand Binding, Mol. Cell. Biol., 21, 6071, 10.1128/MCB.21.17.6071-6079.2001 Penton, 2012, Notch signaling in human development and disease, Semin. Cell Dev. Biol., 23, 450, 10.1016/j.semcdb.2012.01.010 Takebe, 2014, Targeting Notch signaling pathway in cancer: clinical development advances and challenges, Pharmacol. Ther., 141, 140, 10.1016/j.pharmthera.2013.09.005 Ranganathan, 2011, Notch signalling in solid tumours: a little bit of everything but not all the time, Nat. Rev. Cancer, 11, 338, 10.1038/nrc3035 Kanamori, 2007, Contribution of Notch signaling activation to human glioblastoma multiforme, J. Neurosurg., 106, 417, 10.3171/jns.2007.106.3.417 Zhang, 2008, Notch activation promotes cell proliferation and the formation of neural stem cell-like colonies in human glioma cells, Mol. Cell. Biochem., 307, 101, 10.1007/s11010-007-9589-0 Phillips, 2006, Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis, Cancer Cell, 9, 157, 10.1016/j.ccr.2006.02.019 Hulleman, 2009, A role for the transcription factor HEY1 in glioblastoma, J. Cell. Mol. Med., 13, 136, 10.1111/j.1582-4934.2008.00307.x Brennan, 2009, Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations, PLoS One, 4, 10.1371/journal.pone.0007752 El Hindy, 2013, Implications of Dll4-Notch signaling activation in primary glioblastoma multiforme, Neuro. Oncol., 15, 1366, 10.1093/neuonc/not071 Zhang, 2012, Notch1 promotes glioma cell migration and invasion by stimulating β-catenin and NF-κB signaling via AKT activation, Cancer Sci., 103, 181, 10.1111/j.1349-7006.2011.02154.x Xing, 2015, Elevated expression of Notch-1 and EGFR induced apoptosis in glioblastoma multiforme patients, Clin. Neurol. Neurosurg., 131, 54, 10.1016/j.clineuro.2015.01.018 Han, 2017, Notch1 ablation radiosensitizes glioblastoma cells, Oncotarget, 8, 88059, 10.18632/oncotarget.21409 Dell’Albani, 2014, Differential patterns of NOTCH1-4 receptor expression are markers of glioma cell differentiation, Neuro. Oncol., 16, 204, 10.1093/neuonc/not168 Margareto, 2007, Gene expression profiling of human gliomas reveals differences between GBM and LGA related to energy metabolism and notch signaling pathways, J. Mol. Neurosci., 32, 53, 10.1007/s12031-007-0008-5 Hai, 2018, Notch1 is a prognostic factor that is distinctly activated in the classical and proneural subtype of glioblastoma and that promotes glioma cell survival via the NF-κB(p65) pathway article, Cell Death Dis., 9, 1, 10.1038/s41419-017-0119-z Cheng, 2017, Bioinformatic analyses reveal a distinct Notch activation induced by STAT3 phosphorylation in the mesenchymal subtype of glioblastoma, J. Neurosurg., 126, 249, 10.3171/2015.11.JNS15432 Verhaak, 2010, Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1, Cancer Cell, 17, 98, 10.1016/j.ccr.2009.12.020 Cooper, 2010, The proneural molecular signature is enriched in oligodendrogliomas and predicts improved survival among diffuse gliomas, PLoS One, 5, 1, 10.1371/journal.pone.0012548 Allen, 2015, Epigenetic Pathways and Glioblastoma Treatment: Insights From Signaling Cascades, J. Cell. Biochem., 116, 351, 10.1002/jcb.24990 Bazzoni, 2019, Role of notch signaling pathway in glioblastoma pathogenesis, Cancers (Basel)., 11, 10.3390/cancers11030292 Tsung, 2017, Methylation regulates HEY1 expression in glioblastoma, Oncotarget, 8, 44398, 10.18632/oncotarget.17897 Sun, 2009, DNER, an epigenetically modulated gene, regulates glioblastoma-derived neurosphere cell differentiation and tumor propagation, Stem Cells, 27, 1473, 10.1002/stem.89 Velásquez, 2019, Molecular and clinical insights into the invasive capacity of glioblastoma cells, J. Oncol., 2019, 10.1155/2019/1740763 Jiang, 2014, Targeting glioma stem cells via the Hedgehog signaling pathway, Neuroimmunol. Neuroinflammation., 1, 51, 10.4103/2347-8659.139715 Dlugosz, 2009, Following the hedgehog to new cancer therapies, N. Engl. J. Med., 361, 1202, 10.1056/NEJMe0906092 Yoo, 2011, Sonic hedgehog pathway promotes metastasis and lymphangiogenesis via activation of Akt, EMT, and MMP-9 pathway in gastric cancer, Cancer Res., 71, 7061, 10.1158/0008-5472.CAN-11-1338 Hayhurst, 2003, Mouse models of holoprosencephaly, Curr. Opin. Neurol., 16, 135, 10.1097/00019052-200304000-00003 Bresler, 2016, Nevoid basal cell carcinoma syndrome (Gorlin syndrome), Head Neck Pathol., 10, 119, 10.1007/s12105-016-0706-9 Caro, 2010, The role of the hedgehog signaling pathway in the development of basal cell carcinoma and opportunities for treatment, Clin. Cancer Res., 16, 3335, 10.1158/1078-0432.CCR-09-2570 Wu, 2017, Hedgehog signaling: from basic biology to Cancer therapy, Cell Chem. Biol., 24, 252, 10.1016/j.chembiol.2017.02.010 Giroux-Leprieur, 2018, Hedgehog signaling in lung cancer: from oncogenesis to cancer treatment resistance, Int. J. Mol. Sci., 19, 10.3390/ijms19092835 Clement, 2007, HEDGEHOG-GLI1 signaling regulates human glioma growth, Cancer stem cell self-renewal, and tumorigenicity, Curr. Biol., 17, 165, 10.1016/j.cub.2006.11.033 Allen, 2011, Overlapping roles and collective requirement for the coreceptors GAS1, CDO, and BOC in SHH pathway function, Dev. Cell, 20, 775, 10.1016/j.devcel.2011.04.018 Robbins, 2012, The hedgehog signal transduction network, Sci. Signal., 5, 10.1126/scisignal.2002906 Wang, 2019, Advancement of multi-target drug discoveries and promising applications in the field of Alzheimer’s disease, Eur. J. Med. Chem., 169, 200, 10.1016/j.ejmech.2019.02.076 Bar, 2007, Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like Cancer cells in glioblastoma, Stem Cells, 25, 2524, 10.1634/stemcells.2007-0166 Zbinden, 2010, NANOG regulates glioma stem cells and is essential in vivo acting in a cross-functional network with GLI1 and p53, EMBO J., 29, 2659, 10.1038/emboj.2010.137 Ehtesham, 2007, Ligand-dependent activation of the hedgehog pathway in glioma progenitor cells, Oncogene, 26, 5752, 10.1038/sj.onc.1210359 Rimkus, 2018, Truncated glioma-associated oncogene homolog 1 (tGLI1) mediates mesenchymal glioblastoma via transcriptional activation of CD44, Cancer Res., 78, 2589, 10.1158/0008-5472.CAN-17-2933 Sirkisoon, 2018, Interaction between STAT3 and GLI1/tGLI1 oncogenic transcription factors promotes the aggressiveness of triple-negative breast cancers and HER2-enriched breast cancer, Oncogene, 37, 2502, 10.1038/s41388-018-0132-4 Wang, 2010, Sonic Hedgehog/GLI1 signaling pathway inhibition restricts cell migration and invasion in human gliomas, Neurol. Res., 32, 975, 10.1179/016164110X12681290831360 Uchida, 2011, Role of sonic hedgehog signaling in migration of cell lines established from CD133-positive malignant glioma cells, J. Neurooncol., 104, 697, 10.1007/s11060-011-0552-2 Wang, 2015, BRD4 induces cell migration and invasion in HCC cells through MMP-2 and MMP-9 activation mediated by the Sonic hedgehog signaling pathway, Oncol. Lett., 10, 2227, 10.3892/ol.2015.3570 Tang, 2014, Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition, Nat. Med., 20, 732, 10.1038/nm.3613 Malatesta, 2013, Histone acetyltransferase PCAF is required for hedgehog-Gli-dependent transcription and cancer cell proliferation, Cancer Res., 73, 6323, 10.1158/0008-5472.CAN-12-4660 McCord, 2017, Targeting WNT signaling for multifaceted glioblastoma therapy, Front. Cell. Neurosci., 11, 10.3389/fncel.2017.00318 Logan, 2004, The Wnt signaling pathway in development and disease, Annu. Rev. Cell Dev. Biol., 20, 781, 10.1146/annurev.cellbio.20.010403.113126 D’Alimonte, 2013, Adenosine A1 receptor stimulation enhances osteogenic differentiation of human dental pulp-derived mesenchymal stem cells via WNT signaling, Stem Cell Res., 11, 611, 10.1016/j.scr.2013.04.002 D’Alimonte, 2013, Wnt signaling behaves as a “Master regulator” in the osteogenic and adipogenic commitment of human amniotic fluid mesenchymal stem cells, Stem Cell Rev. Reports., 9, 642, 10.1007/s12015-013-9436-5 McMahon, 1990, The Wnt-1 (int-1) proto-oncogene is required for development of a large region of the mouse brain, Cell, 62, 1073, 10.1016/0092-8674(90)90385-R Thomas, 1990, Targeted disruption of the murine int-1 proto-oncogene resulting in severe abnormalities in midbrain and cerebellar development, Nature, 346, 847, 10.1038/346847a0 Zhou, 2004, Severe defects in dorsal thalamic development in low-density lipoprotein receptor-related protein-6 mutants, J. Neurosci., 24, 7632, 10.1523/JNEUROSCI.2123-04.2004 Klaus, 2008, Wnt signalling and its impact on development and cancer, Nat. Rev. Cancer, 8, 387, 10.1038/nrc2389 Zhan, 2017, Wnt signaling in cancer, Oncogene, 36, 1461, 10.1038/onc.2016.304 Chen, 2011, β-catenin/Tcf-4 complex transcriptionally regulates AKT1 in glioma, Int. J. Oncol., 39, 883 Zarkou, 2018, Crosstalk mechanisms between the WNT signaling pathway and long non-coding RNAs, Noncoding RNA Res., 3, 42, 10.1016/j.ncrna.2018.04.001 Widelitz, 2005, Wnt signaling through canonical and non-canonical pathways: recent progress, Growth Factors, 23, 111, 10.1080/08977190500125746 Niehrs, 2012, The complex world of WNT receptor signalling, Nat. Rev. Mol. Cell Biol., 13, 767, 10.1038/nrm3470 He, 1999, PPARδ is an APC-regulated target of nonsteroidal anti-inflammatory drugs, Cell, 99, 335, 10.1016/S0092-8674(00)81664-5 Wielenga, 1999, Expression of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway, Am. J. Pathol., 154, 515, 10.1016/S0002-9440(10)65297-2 Blache, 2004, SOX9 is an intestine crypt transcription factor, is regulated by the Wnt pathway, and represses the CDX2 and MUC2 genes, J. Cell Biol., 166, 37, 10.1083/jcb.200311021 Shu, 2005, Wnt/β-catenin signaling acts upstream of N-myc, BMP4, and FGF signaling to regulate proximal-distal patterning in the lung, Dev. Biol., 283, 226, 10.1016/j.ydbio.2005.04.014 Valenta, 2012, The many faces and functions of Î 2-catenin, EMBO J., 31, 2714, 10.1038/emboj.2012.150 Bhuvanalakshmi, 2019, Stemness, pluripotentiality, and wnt antagonism: SFRP4, a wnt antagonist mediates pluripotency and stemness in glioblastoma, Cancers (Basel)., 11, 25, 10.3390/cancers11010025 Wang, 2017, Cyclophilin A maintains glioma-initiating cell stemness by regulating Wnt/β-catenin signaling, Clin. Cancer Res., 23, 6640, 10.1158/1078-0432.CCR-17-0774 Denysenko, 2016 Gong, 2012, FoxM1 and Wnt/β-catenin signaling in glioma stem cells, Cancer Res., 72, 5658, 10.1158/0008-5472.CAN-12-0953 Zheng, 2010, PLAGL2 regulates wnt signaling to impede differentiation in neural stem cells and gliomas, Cancer Cell, 17, 497, 10.1016/j.ccr.2010.03.020 Jin, 2011, Frizzled 4 regulates stemness and invasiveness of migrating glioma cells established by serial intracranial transplantation, Cancer Res., 71, 3066, 10.1158/0008-5472.CAN-10-1495 Holland, 2013, Wnt signaling in stem and cancer stem cells, Curr. Opin. Cell Biol., 25, 254, 10.1016/j.ceb.2013.01.004 Noda, 2009, Activation of WntB-catenin signalling pathway induces chemoresistance to interferon-α5-fluorouracil combination therapy for hepatocellular carcinoma, Br. J. Cancer, 100, 1647, 10.1038/sj.bjc.6605064 Woodward, 2007, WNT/β-catenin mediates radiation resistance of mouse mammary progenitor cells, Proc. Natl. Acad. Sci. U. S. A., 104, 618, 10.1073/pnas.0606599104 Sandberg, 2013, Comparison of glioma stem cells to neural stem cells from the adult human brain identifies dysregulated Wnt- signaling and a fingerprint associated with clinical outcome, Exp. Cell Res., 319, 2230, 10.1016/j.yexcr.2013.06.004 Zhang, 2012, Wnt/beta-catenin signaling in glioma, J. Neuroimmune Pharmacol., 7, 740, 10.1007/s11481-012-9359-y Nager, 2012, Β -Catenin signalling in glioblastoma multiforme and glioma-initiating cells, Chemother. Res. Pract., 2012, 1, 10.1155/2012/192362 Zhang, 2010, Selective targeting of radiation-resistant tumor-initiating cells, Proc. Natl. Acad. Sci. U. S. A., 107, 3522, 10.1073/pnas.0910179107 Auger, 2006, Genetic alterations associated with acquired temozolomide resistance in SNB-19, a human glioma cell line, Mol. Cancer Ther., 5, 2182, 10.1158/1535-7163.MCT-05-0428 Kahlert, 2012, Activation of canonical WNT/β-catenin signaling enhances in vitro motility of glioblastoma cells by activation of ZEB1 and other activators of epithelial-to-mesenchymal transition, Cancer Lett., 325, 42, 10.1016/j.canlet.2012.05.024 Arnés, 2017, Aberrant Wnt signaling: a special focus in CNS diseases, J. Neurogenet., 31, 216, 10.1080/01677063.2017.1338696 Santiago, 2017, Wnt signaling pathway protein LEF1 in cancer, as a biomarker for prognosis and a target for treatment, Am. J. Cancer Res., 7, 1389 Duan, 2015, HOXA13 is a potential GBM diagnostic marker and promotes glioma invasion by activating the Wnt and TGF-β pathways, Oncotarget, 6, 27778, 10.18632/oncotarget.4813 Götze, 2010, Frequent promoter hypermethylation of Wnt pathway inhibitor genes in malignant astrocytic gliomas, Int. J. Cancer, 126, 10.1002/ijc.24981 Lambiv, 2011, The Wnt inhibitory factor 1 (WIF1) is targeted in glioblastoma and has a tumor suppressing function potentially by induction of senescence, Neuro. Oncol., 13, 736, 10.1093/neuonc/nor036 Vassallo, 2016, WIF1 re-expression in glioblastoma inhibits migration through attenuation of non-canonical WNT signaling by downregulating the lncRNA MALAT1, Oncogene, 35, 12, 10.1038/onc.2015.61 Guo, 2014, The expression of Wnt-inhibitor DKK1 (Dickkopf 1) is determined by intercellular crosstalk and hypoxia in human malignant gliomas, J. Cancer Res. Clin. Oncol., 140, 1261, 10.1007/s00432-014-1642-2 Jones, 2012, Functions of DNA methylation: islands, start sites, gene bodies and beyond, Nat. Rev. Genet., 13, 484, 10.1038/nrg3230 Lövkvist, 2016, DNA methylation in human epigenomes depends on local topology of CpG sites, Nucleic Acids Res., 44, 5123, 10.1093/nar/gkw124 Bird, 2002, DNA methylation patterns and epigenetic memory, Genes Dev., 16, 6, 10.1101/gad.947102 de Souza, 2018, A distinct DNA methylation shift in a subset of glioma CpG island methylator phenotypes during tumor recurrence, Cell Rep., 23, 637, 10.1016/j.celrep.2018.03.107 Liao, 2018, Models of epigenetic age capture patterns of DNA methylation in glioma associated with molecular subtype, survival, and recurrence, Neuro. Oncol., 20, 942, 10.1093/neuonc/noy003 Qu, 2013, Gene methylation in gastric cancer, Clin. Chim. Acta, 424, 53, 10.1016/j.cca.2013.05.002 Choudhury, 2015, Selective increase in subtelomeric DNA methylation: an epigenetic biomarker for malignant glioma, Clin. Epigenetics, 7, 10.1186/s13148-015-0140-y Jin, 2017, MiR-424 functions as a tumor suppressor in glioma cells and is down-regulated by DNA methylation, J. Neurooncol., 133, 247, 10.1007/s11060-017-2438-4 Fernandez, 2018, Loss of 5hmC identifies a new type of aberrant DNA hypermethylation in glioma, Hum. Mol. Genet., 27, 3046, 10.1093/hmg/ddy214 Kraus, 2012, Low values of 5-hydroxymethylcytosine (5hmC), the “sixth base,” are associated with anaplasia in human brain tumors, Int. J. Cancer, 131, 1577, 10.1002/ijc.27429 MacK, 2014, Epigenomic alterations define lethal CIMP-positive ependymomas of infancy, Nature, 506, 445, 10.1038/nature13108 Malta, 2018, Glioma CpG island methylator phenotype (G-CIMP): biological and clinical implications, Neuro. Oncol., 20, 608, 10.1093/neuonc/nox183 Jha, 2014, Genome-wide methylation profiling identifies an essential role of reactive oxygen species in pediatric glioblastoma multiforme and validates a methylome specific for H3 histone family 3A with absence of G-CIMP/isocitrate dehydrogenase 1 mutation, Neuro. Oncol., 16, 1607, 10.1093/neuonc/nou113 Watanabe, 2007, Aberrant hypermethylation of p14ARF and O6- methylguanine-DNA methyltransferase genes in astrocytoma progression, Brain Pathol., 17, 5, 10.1111/j.1750-3639.2006.00030.x Lee, 2000, Growth inhibitory effect on glioma cells of adenovirus-mediated p16/INK4a gene transfer in vitro and in vivo, Int. J. Mol. Med., 6, 559 Malgorzata, 2016, NDRG2 and NDRG4 expression is altered in glioblastoma and influences survival in patients with MGMT-methylated tumors - PubMed, Anticancer Res., 36, 887 Gömöri, 2007, Epigenetic inactivation of the hMLH1 gene in progression of gliomas, Diagn. Mol. Pathol., 16, 104, 10.1097/PDM.0b013e318033f140 Esteller, 2000, Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents, N. Engl. J. Med., 343, 1350, 10.1056/NEJM200011093431901 Mur, 2015, Impact on prognosis of the regional distribution of MGMT methylation with respect to the CpG island methylator phenotype and age in glioma patients, J. Neurooncol., 122, 441, 10.1007/s11060-015-1738-9 Xipell, 2016, Endoplasmic reticulum stress-inducing drugs sensitize glioma cells to temozolomide through downregulation of MGMT, MPG, and Rad51, Neuro. Oncol., 18, 1109, 10.1093/neuonc/now022 Yu, 2018, Inhibition of NF-κB results in anti-glioma activity and reduces temozolomide-induced chemoresistance by down-regulating MGMT gene expression, Cancer Lett., 428, 77, 10.1016/j.canlet.2018.04.033 Jiang, 2006, Promoter hypermethylation-mediated down-regulation of LATS1 and LATS2 in human astrocytoma, Neurosci. Res., 56, 450, 10.1016/j.neures.2006.09.006 Watanabe, 2002, Methylation of the p73 gene in gliomas, Acta Neuropathol., 104, 357, 10.1007/s00401-002-0549-1 Newcomb, 2000, Incidence of p14(arf) gene deletion in high-grade adult and pediatric astrocytomas, Hum. Pathol., 31, 115, 10.1016/S0046-8177(00)80207-5 Deng, 2003, N-Myc downstream-regulated gene 2 (NDRG2) inhibits glioblastoma cell proliferation, Int. J. Cancer, 106, 342, 10.1002/ijc.11228 Berghoff, 2015, Assessing MGMT methylation status and its current impact on treatment in glioblastoma, CNS Oncol., 4, 47, 10.2217/cns.14.50 Kanemoto, 2014, Prognostic prediction of glioblastoma by quantitative assessment of the methylation status of the entire MGMT promoter region, BMC Cancer, 14, 641, 10.1186/1471-2407-14-641 Weller, 2013, Assessing the MGMT status in glioblastoma: One step forward, two steps back?, Neuro. Oncol., 15, 253, 10.1093/neuonc/not014 Alaminos, 2005, EMP3, a Myelin-Related Gene Located in the Critical 19q13.3 Region, Is Epigenetically Silenced and Exhibits Features of a Candidate Tumor Suppressor in Glioma and Neuroblastoma, Cancer Res., 65, 2565, 10.1158/0008-5472.CAN-04-4283 Kunitz, 2007, DNA hypermethylation and aberrant expression of the EMP3 gene at 19q13.3 in human gliomas, Brain Pathol., 17, 363, 10.1111/j.1750-3639.2007.00083.x Wang, 2018, Krüppel-like factor 4 (KLF4) induces mitochondrial fusion and increases spare respiratory capacity of human glioblastoma cells, J. Biol. Chem., 293, 6544, 10.1074/jbc.RA117.001323 Nakahara, 2010, Genetic and epigenetic inactivation of Kruppel-like Factor 4 in medulloblastoma, Neoplasia, 12, 20, 10.1593/neo.91122 Landré, 2016, p73 promotes glioblastoma cell invasion by directly activating POSTN (periostin) expression, Oncotarget, 7, 11785, 10.18632/oncotarget.7600 Funato, 2018, <Scp>SIRT</scp> 2‐mediated inactivation of p73 is required for glioblastoma tumorigenicity, EMBO Rep., 19, 10.15252/embr.201745587 Waha, 2010, Epigenetic downregulation of mitogen-activated protein kinase phosphatase MKP-2 relieves its growth suppressive activity in glioma cells, Cancer Res., 70, 1689, 10.1158/0008-5472.CAN-09-3218 Berdasco, 2009, Epigenetic inactivation of the Sotos overgrowth syndrome gene histone methyltransferase NSD1 in human neuroblastoma and glioma, Proc. Natl. Acad. Sci. U. S. A., 106, 21830, 10.1073/pnas.0906831106 Moradimotlagh, 2020, MicroRNA-129 inhibits glioma cell growth by targeting CDK4, CDK6, and MDM2, Mol. Ther. - Nucleic Acids., 19, 759, 10.1016/j.omtn.2019.11.033 Yadavilli, 2015, The emerging role of NG2 in pediatric diffuse intrinsic pontine glioma, Oncotarget, 6, 12141, 10.18632/oncotarget.3716 Dong, 2015, Downregulation of HTATIP2 expression is associated with promoter methylation and poor prognosis in glioma, Exp. Mol. Pathol., 98, 192, 10.1016/j.yexmp.2015.01.013 Chu, 2014, In vitro and in vivo radiosensitization of human glioma U251 cells induced by upregulated expression of SLC22A18, Cancer Gene Ther., 21, 103, 10.1038/cgt.2014.4 Chu, 2011, Elevated expression of solute carrier family 22 member 18 increases the sensitivity of U251 glioma cells to BCNU, Oncol. Lett., 2, 1139, 10.3892/ol.2011.371 Chu, 2020, Evaluation of combination gene therapy with SLC22A18 upregulation and sequence binding protein 1 downregulation for glioma U251 cells in vitro and in vivo, Glioma, 3, 16, 10.4103/glioma.glioma_19_19 von dem Knesebeck, 2012, RANK (TNFRSF11A) is Epigenetically inactivated and induces apoptosis in gliomas, Neoplasia (United States)., 14, 526, 10.1596/neo.12360 Wu, 2012, Down-regulation of neogenin accelerated glioma progression through promoter methylation and its overexpression in SHG-44 induced apoptosis, PLoS One, 7 Villanueva, 2017, The Netrin-4/Neogenin-1 axis promotes neuroblastoma cell survival and migration, Oncotarget, 8, 9767, 10.18632/oncotarget.14213 Kadowaki, 2012, DNA methylation-mediated silencing of nonsteroidal anti-inflammatory drug-activated gene (NAG-1/GDF15) in glioma cell lines, Int. J. Cancer, 130, 267, 10.1002/ijc.26082 Li, 2013, Glioma pathogenesis-related protein 1 induces prostate cancer cell death through Hsc70-mediated suppression of AURKA and TPX2, Mol. Oncol., 7, 484, 10.1016/j.molonc.2012.12.005 Bai, 2014, Downregulation of TES by hypermethylation in glioblastoma reduces cell apoptosis and predicts poor clinical outcome, Eur. J. Med. Res., 19, 66, 10.1186/s40001-014-0066-4 Foltz, 2006, Genome-wide analysis of epigenetic silencing identifies BEX1 and BEX2 as candidate tumor suppressor genes in malignant glioma, Cancer Res., 66, 6665, 10.1158/0008-5472.CAN-05-4453 Le Mercier, 2009, Galectin 1 proangiogenic and promigratory effects in the Hs683 oligodendroglioma model are partly mediated through the control of BEX2 expression1, Neoplasia, 11, 485, 10.1593/neo.81526 Moniz, 2013, Loss of WNK2 expression by promoter gene methylation occurs in adult gliomas and triggers Rac1-mediated tumour cell invasiveness, Hum. Mol. Genet., 22, 84, 10.1093/hmg/dds405 Xu, 2010, Slit2/Robo1 signaling in glioma migration and invasion, Neurosci. Bull., 26, 474, 10.1007/s12264-010-0730-9 Zhang, 2017, MicroRNA.124 inhibits the proliferation of C6 glioma cells by targeting Smad4, Int. J. Mol. Med., 40, 1226, 10.3892/ijmm.2017.3088 Fowler, 2011, MiR-124a is frequently down-regulated in glioblastoma and is involved in migration and invasion, Eur. J. Cancer, 47, 953, 10.1016/j.ejca.2010.11.026 Gessler, 2011, Knockdown of TFPI-2 promotes migration and invasion of glioma cells, Neurosci. Lett., 497, 49, 10.1016/j.neulet.2011.04.027 Konduri, 2001, A novel function of tissue factor pathway inhibitor-2 (TFPI-2) in human glioma invasion, Oncogene, 20, 6938, 10.1038/sj.onc.1204847 Vaitkienė, 2012, Associations between TFPI-2 methylation and poor prognosis in glioblastomas Paulina Vaitkienė, Daina Skiriutė, kęstutis skauminas, Medicina (B. Aires), 48, 51, 10.3390/medicina48070051 Echizen, 2014, PCDH10 is required for the tumorigenicity of glioblastoma cells, Biochem. Biophys. Res. Commun., 444, 13, 10.1016/j.bbrc.2013.12.138 Mei, 2011, RUNX3 expression is lost in glioma and its restoration causes drastic suppression of tumor invasion and migration, J. Cancer Res. Clin. Oncol., 137, 1823, 10.1007/s00432-011-1063-4 De Ruijter, 2003, Histone deacetylases (HDACs): characterization of the classical HDAC family, Biochem. J., 370, 737, 10.1042/bj20021321 Wang, 2014, Visualizing epigenetics: current advances and advantages in HDAC PET imaging techniques, Neuroscience, 264, 186, 10.1016/j.neuroscience.2013.09.018 Mathias, 2015, Post-translational modifications regulate class IIa histone deacetylase (HDAC) function in health and disease, Mol. Cell Proteomics, 14, 456, 10.1074/mcp.O114.046565 Liu, 2011, Optimization of cellular activity of G9a inhibitors 7-aminoalkoxy- quinazolines, J. Med. Chem., 54, 6139, 10.1021/jm200903z Zang, 2014, SAHA-based novel HDAC inhibitor design by core hopping method, J. Mol. Graph. Model., 54, 10, 10.1016/j.jmgm.2014.08.005 Wang, 2017, Knockdown of HDAC1 expression suppresses invasion and induces apoptosis in glioma cells, Oncotarget, 8, 48027, 10.18632/oncotarget.18227 Leng, 2016, Valproic acid and other HDAC inhibitors upregulate FGF21 gene expression and promote process elongation in Glia by inhibiting HDAC2 and 3, Int. J. Neuropsychopharmacol., 19, 10.1093/ijnp/pyw035 Milde, 2010, HDAC5 and HDAC9 in medulloblastoma: novel markers for risk stratification and role in tumor cell growth, Clin. Cancer Res., 16, 3240, 10.1158/1078-0432.CCR-10-0395 Lucio-Eterovic, 2008, Differential expression of 12 histone deacetylase (HDAC) genes in astrocytomas and normal brain tissue: class II and IV are hypoexpressed in glioblastomas, BMC Cancer, 8, 10.1186/1471-2407-8-243 Shi, 2016, Phase I trial of panobinostat and fractionated stereotactic re-irradiation therapy for recurrent high grade gliomas, J. Neurooncol., 127, 535, 10.1007/s11060-016-2059-3 Ghiaseddin, 2018, Phase II study of Bevacizumab and vorinostat for patients with recurrent world health organization grade 4 malignant glioma, Oncologist, 23, 157, 10.1634/theoncologist.2017-0501 Marks, 2007, Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug, Nat. Biotechnol., 25, 84, 10.1038/nbt1272 Chang, 2009, Structural basis for G9a-like protein lysine methyltransferase inhibition by BIX-01294, Nat. Struct. Mol. Biol., 16, 312, 10.1038/nsmb.1560 Cheung, 2012, Constitutional tandem duplication of 9q34 that truncates EHMT1 in a child with ganglioglioma, Pediatr. Blood Cancer, 58, 801, 10.1002/pbc.23219 Liu, 2013, Discovery of an in vivo chemical probe of the lysine methyltransferases G9a and GLP, J. Med. Chem., 56, 8931, 10.1021/jm401480r Kondengaden, 2016, Discovery of novel small molecule inhibitors of lysine methyltransferase G9a and their mechanism in leukemia cell lines, Eur. J. Med. Chem., 122, 382, 10.1016/j.ejmech.2016.06.028 Wiese, 2016, No significant cytotoxic effect of the EZH2 inhibitor tazemetostat (EPZ-6438) on pediatric glioma cells with wildtype histone 3 or mutated histone 3.3, Klin. Padiatr., 228, 113, 10.1055/s-0042-105292 Banasavadi-Siddegowda, 2018, PRMT5 as a druggable target for glioblastoma therapy, Neuro. Oncol., 20, 753, 10.1093/neuonc/nox206 Heddleston, 2012, Hypoxia-induced mixed-lineage leukemia 1 regulates glioma stem cell tumorigenic potential, Cell Death Differ., 19, 428, 10.1038/cdd.2011.109 Zhou, 2016, Pygo2 functions as a prognostic factor for glioma due to its up-regulation of H3K4me3 and promotion of MLL1/MLL2 complex recruitment, Sci. Rep., 6 Sharma, 2010, HDAC inhibitor, scriptaid, induces glioma cell apoptosis through JNK activation and inhibits telomerase activity, J. Cell. Mol. Med., 14, 2151, 10.1111/j.1582-4934.2009.00844.x Vargas, 2014, Inhibition of HDAC increases the senescence induced by natural polyphenols in glioma cells, Biochem. Cell Biol., 92, 297, 10.1139/bcb-2014-0022 Ghildiyal, 2017, Concerted action of histone methyltransferases G9a and PRMT-1 regulates PGC-1α-RIG-I axis in IFNγ treated glioma cells, Cytokine, 89, 185, 10.1016/j.cyto.2015.12.008 Guo, 2016, Mechanism of G9a inhibitor BIX-01294 acting on U251 glioma cells, Mol. Med. Rep., 14, 4613, 10.3892/mmr.2016.5815 Orzan, 2011, Enhancer of Zeste 2 (EZH2) is up-regulated in malignant gliomas and in glioma stem-like cells, Neuropathol. Appl. Neurobiol., 37, 381, 10.1111/j.1365-2990.2010.01132.x Chen, 2017, EZH2 palmitoylation mediated by ZDHHC5 in p53-mutant glioma drives malignant development and progression, Cancer Res., 77, 4998, 10.1158/0008-5472.CAN-17-1139 Kurmasheva, 2017, Initial testing (stage 1) of tazemetostat (EPZ-6438), a novel EZH2 inhibitor, by the Pediatric Preclinical Testing Program, Pediatr. Blood Cancer, 64, 10.1002/pbc.26218 Zhang, 2017, Combination of EZH2 inhibitor and BET inhibitor for treatment of diffuse intrinsic pontine glioma, Cell Biosci., 7, 10.1186/s13578-017-0184-0 Schwartzentruber, 2012, Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma, Nature, 482, 226, 10.1038/nature10833 Stanton, 2017, A general non-radioactive ATPase assay for chromatin remodeling complexes, Curr. Protoc. Chem. Biol., 9, 1, 10.1002/cpch.16 Marfella, 2009, A mutation in the mouse Chd2 chromatin remodeling enzyme results in a complex renal phenotype, Kidney Blood Press. Res., 31, 421, 10.1159/000190788 Choi, 2015, Mutation of HELLS, a chromatin remodeling gene, gastric and colorectal cancers, Pathol. Oncol. Res., 21, 851, 10.1007/s12253-014-9862-y Liau, 2017, Adaptive chromatin remodeling drives glioblastoma stem cell plasticity and drug tolerance, Cell Stem Cell, 20, 233, 10.1016/j.stem.2016.11.003 Xiao, 2017, Chromatin remodeling factor LSH is upregulated by the LRP6-GSK3β-E2F1 axis linking reversely with survival in gliomas, Theranostics, 7, 132, 10.7150/thno.17032 Zhao, 2020, Single nucleotide alterations in MicroRNAs and human cancer-A not fully explored field, Noncoding RNA Res., 5, 27, 10.1016/j.ncrna.2020.02.003 ElKhouly, 2020, MicroRNA-486-5p and microRNA-486-3p: Multifaceted pleiotropic mediators in oncological and non-oncological conditions, Noncoding RNA Res., 5, 11, 10.1016/j.ncrna.2020.01.001 Kwok, 2017, Translational applications of microRNAs in cancer, and therapeutic implications, Noncoding RNA Res., 2, 143, 10.1016/j.ncrna.2017.12.002 Rajgor, 2018, Macro roles for microRNAs in neurodegenerative diseases, Noncoding RNA Res., 3, 154, 10.1016/j.ncrna.2018.07.001 Sekar, 2019, Circular RNA expression and function in the brain, Noncoding RNA Res., 4, 23, 10.1016/j.ncrna.2019.01.001 Rasool, 2016, Non-coding RNAs in cancer diagnosis and therapy, Noncoding RNA Res., 1, 69, 10.1016/j.ncrna.2016.11.001 Alfardus, 2017, MicroRNA regulation of glycolytic metabolism in glioblastoma, Biomed Res. Int., 2017, 10.1155/2017/9157370 Dai, 2013, Decreased miR-106a inhibits glioma cell glucose uptake and proliferation by targeting SLC2A3 in GBM, BMC Cancer, 13, 478, 10.1186/1471-2407-13-478 Zhao, 2013, MiR-143 inhibits glycolysis and depletes stemness of glioblastoma stem-like cells, Cancer Lett., 333, 253, 10.1016/j.canlet.2013.01.039 Kefas, 2010, Pyruvate kinase M2 is a target of the tumorsuppressive microRNA-326 and regulates the survival of glioma cells, Neuro. Oncol., 12, 1102, 10.1093/neuonc/noq080 Luan, 2015, PKM2 promotes glucose metabolism and cell growth in gliomas through a mechanism involving a let-7a/c-Myc/hnRNPA1 feedback loop, Oncotarget, 6, 13006, 10.18632/oncotarget.3514 Liu, 2017, MicroRNA-153 regulates glutamine metabolism in glioblastoma through targeting glutaminase, Tumor Biol., 39 Xu, 2016, ATP5A1 and ATP5B are highly expressed in glioblastoma tumor cells and endothelial cells of microvascular proliferation, J. Neurooncol., 126, 405, 10.1007/s11060-015-1984-x Yang, 2012, EGFR-Induced and PKCε Monoubiquitylation-Dependent NF-κB Activation Upregulates PKM2 Expression and Promotes Tumorigenesis, Mol. Cell, 48, 771, 10.1016/j.molcel.2012.09.028 Rao, 2010, Genome-wide expression profiling identifies deregulated miRNAs in malignant astrocytoma, Mod. Pathol., 23, 1404, 10.1038/modpathol.2010.135 Rao, 2013, miR-219-5p inhibits receptor tyrosine kinase pathway by targeting EGFR in glioblastoma, PLoS One, 8, 10.1371/journal.pone.0063164 Kefas, 2008, microRNA-7 inhibits the epidermal growth factor receptor and the akt pathway and is down-regulated in glioblastoma, Cancer Res., 68, 3566, 10.1158/0008-5472.CAN-07-6639 Papagiannakopoulos, 2012, Pro-neural miR-128 is a glioma tumor suppressor that targets mitogenic kinases, Oncogene, 31, 1884, 10.1038/onc.2011.380 Chan, 2005, MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells, Cancer Res., 65, 6029, 10.1158/0008-5472.CAN-05-0137 Zhou, 2010, Downregulation of miR-21 inhibits EGFR pathway and suppresses the growth of human glioblastoma cells independent of PTEN status, Lab. Investig., 90, 144, 10.1038/labinvest.2009.126 Gaglio, 2011, Oncogenic K‐Ras decouples glucose and glutamine metabolism to support cancer cell growth, Mol. Syst. Biol., 7, 523, 10.1038/msb.2011.56 Kim, 2010, Integrative genome analysis reveals an oncomir/ oncogene cluster regulating glioblastoma survivorship, Proc. Natl. Acad. Sci. U. S. A., 107, 2183, 10.1073/pnas.0909896107 Zhang, 2014, Multiple receptor tyrosine kinases converge on microRNA-134 to control KRAS, STAT5B, and glioblastoma, Cell Death Differ., 21, 720, 10.1038/cdd.2013.196 Tan, 2012, The CREB-miR-9 negative feedback minicircuitry coordinates the migration and proliferation of glioma cells, PLoS One, 7, 10.1371/journal.pone.0049570 Wu, 2013, Increased expression of microRNA-9 predicts an unfavorable prognosis in human glioma, Mol. Cell. Biochem., 384, 263, 10.1007/s11010-013-1805-5 Masui, 2013, MTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc, Cell Metab., 18, 726, 10.1016/j.cmet.2013.09.013 Rodríguez-García, 2017, TGF-β1 targets Smad, p38 MAPK, and PI3K/Akt signaling pathways to induce PFKFB3 gene expression and glycolysis in glioblastoma cells, FEBS J., 284, 3437, 10.1111/febs.14201 Wang, 2019, Inhibition of glycolytic metabolism in glioblastoma cells by Pt3glc combinated with PI3K inhibitor via SIRT3-mediated mitochondrial and PI3K/Akt-MAPK pathway, J. Cell. Physiol., 234, 5888, 10.1002/jcp.26474 Liu, 2014, miR-7 inhibits glioblastoma growth by simultaneously interfering with the PI3K/ATK and Raf/MEK/ERK pathways, Int. J. Oncol., 44, 1571, 10.3892/ijo.2014.2322 Cai, 2015, MicroRNA-542-3p suppresses tumor cell invasion via targeting AKT pathway in human astrocytoma, J. Biol. Chem., 290, 24678, 10.1074/jbc.M115.649004 Zhang, 2014, MicroRNA-503 acts as a tumor suppressor in glioblastoma for multiple antitumor effects by targeting IGF-1R, Oncol. Rep., 31, 1445, 10.3892/or.2013.2951 Guo, 2013, C-Myc negatively controls the tumor suppressor PTEN by upregulating miR-26a in glioblastoma multiforme cells, Biochem. Biophys. Res. Commun., 441, 186, 10.1016/j.bbrc.2013.10.034 Xia, 2015, MicroRNA-1908 functions as a glioblastoma oncogene by suppressing PTEN tumor suppressor pathway, Mol. Cancer, 14, 154, 10.1186/s12943-015-0423-0 Li, 2015, miR-494-3p regulates cellular proliferation, invasion, migration, and apoptosis by PTEN/AKT signaling in human glioblastoma cells, Cell. Mol. Neurobiol., 35, 679, 10.1007/s10571-015-0163-0 Liu, 2013, TGF-β-induced miR10a/b expression promotes human glioma cell migration by targeting PTEN, Mol. Med. Rep., 8, 1741, 10.3892/mmr.2013.1709 Heiden, 2009, Understanding the warburg effect: the metabolic requirements of cell proliferation, Science (80-.), 324, 1029, 10.1126/science.1160809 Shen, 2015, MicroRNA-199a-3p suppresses glioma cell proliferation by regulating the AKT/mTOR signaling pathway, Tumor Biol., 36, 6929, 10.1007/s13277-015-3409-z Rathod, 2014, Tumor suppressive miRNA-34a suppresses cell proliferation and tumor growth of glioma stem cells by targeting Akt and Wnt signaling pathways, FEBS Open Bio, 4, 485, 10.1016/j.fob.2014.05.002 Michlewski, 2010, Antagonistic role of hnRNP A1 and KSRP in the regulation of let-7a biogenesis, Nat. Struct. Mol. Biol., 17, 1011, 10.1038/nsmb.1874 Cheng, 2015, Glucose-mediated N-glycosylation of SCAP is essential for SREBP-1 activation and tumor growth, Cancer Cell, 28, 569, 10.1016/j.ccell.2015.09.021 Ru, 2016, Feedback loop regulation of SCAP/SREBP-1 by miR-29 modulates EGFR signaling-driven glioblastoma growth, Cell Rep., 16, 1527, 10.1016/j.celrep.2016.07.017 Ru, 2017, microRNA-29 mediates a novel negative feedback loop to regulate SCAP/SREBP-1 and lipid metabolism, RNA Dis., 4 Berindan-Neagoe, 2014, MicroRNAome genome: a treasure for cancer diagnosis and therapy, CA Cancer J. Clin., 64, 311, 10.3322/caac.21244 Lakomy, 2011, MiR-195, miR-196b, miR-181c, miR-21 expression levels and O-6-methylguanine-DNA methyltransferase methylation status are associated with clinical outcome in glioblastoma patients, Cancer Sci., 102, 2186, 10.1111/j.1349-7006.2011.02092.x Zang, 2018, Potential epigenetic-based therapeutic targets for glioma, Front. Mol. Neurosci., 11, 408, 10.3389/fnmol.2018.00408 Zhang, 2012, High level of miR-221/222 confers increased cell invasion and poor prognosis in glioma, J. Transl. Med., 10, 119, 10.1186/1479-5876-10-119 Zhang, 2009, Co-suppression of miR-221/222 cluster suppresses human glioma cell growth by targeting p27kip1 in vitro and in vivo, Int. J. Oncol., 34, 1653 Shankaraiah, 2018, Non-coding RNAs in the reprogramming of glucose metabolism in cancer, Cancer Lett., 419, 167, 10.1016/j.canlet.2018.01.048 Balas, 2018, Exploring the mechanisms behind long noncoding RNAs and cancer, Noncoding RNA Res., 3, 108, 10.1016/j.ncrna.2018.03.001 Grixti, 2020, Long noncoding RNAs and their link to cancer, Noncoding RNA Res., 5, 77, 10.1016/j.ncrna.2020.04.003 Ayers, 2018, Non-coding RNA influences in dementia, Noncoding RNA Res., 3, 188, 10.1016/j.ncrna.2018.09.002 An, 2018, NEAT1 and paraspeckles in neurodegenerative diseases: A missing lnc found?, Noncoding RNA Res., 3, 243, 10.1016/j.ncrna.2018.11.003 Chen, 2017, LncRNA‐TP53TG1 participated in the stress response under glucose deprivation in glioma, J. Cell. Biochem., 118, 4897, 10.1002/jcb.26175 Wang, 2017, LEF1-AS1, a long-noncoding RNA, promotes malignancy in glioblastoma, Onco. Targets. Ther., 10, 4251, 10.2147/OTT.S130365 Yang, 2018, Novel role of FBXW7 circular RNA in repressing glioma tumorigenesis, JNCI J. Natl. Cancer Inst., 110, 304, 10.1093/jnci/djx166 Norozi, 2016, Mesenchymal stem cells as a double-edged sword in suppression or progression of solid tumor cells, Tumour Biol. J. Int. Soc. Oncodevelopmental Biol. Med., 37, 11679, 10.1007/s13277-016-5187-7 Cloughesy, 2014, Glioblastoma: from molecular pathology to targeted treatment, Annu. Rev. Pathol., 9, 1, 10.1146/annurev-pathol-011110-130324 Wang, 2015, MicroRNA-873 (miRNA-873) inhibits glioblastoma tumorigenesis and metastasis by suppressing the expression of IGF2BP1, J. Biol. Chem., 290, 8938, 10.1074/jbc.M114.624700 Mo, 2016, MicroRNA-610 suppresses the proliferation of human glioblastoma cells by repressing CCND2 and AKT3, Mol. Med. Rep., 13, 1961, 10.3892/mmr.2016.4760 Clarke, 2013, Epigenetic pathways and glioblastoma treatment, Epigenetics, 8, 785, 10.4161/epi.25440 Sigalotti, 2007, Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications, J. Cell. Physiol., 212, 330, 10.1002/jcp.21066 Rasras, 2018, Genetics and epigenetics of glioblastoma: therapeutic challenges, Clin. Cancer Investig. J., 7, 43, 10.4103/ccij.ccij_82_17 Nebbioso, 2012, Trials with “epigenetic” drugs: an update, Mol. Oncol., 6, 657, 10.1016/j.molonc.2012.09.004 Jin, 2017, Targeting glioma stem cells through combined BMI1 and EZH2 inhibition, Nat. Med., 23, 1352, 10.1038/nm.4415 Yuan, 2017, Synergistic anti-cancer effects of epigenetic drugs on medulloblastoma cells, Cell. Oncol. (Dordr)., 40, 263, 10.1007/s13402-017-0319-7 ClinicalTrials.gov, Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme, (2005). https://clinicaltrials.gov/ct2/show/NCT00238303 (accessed December 10, 2020). ClinicalTrials.gov, Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM), (2010). https://clinicaltrials.gov/ct2/show/NCT01110876 (accessed December 10, 2020). ClinicalTrials.gov, Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma Multiforme, (2008). https://clinicaltrials.gov/ct2/show/NCT00641706 (accessed December 10, 2020). ClinicalTrials.gov, Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas, (2005). https://clinicaltrials.gov/ct2/show/NCT00268385 (accessed December 10, 2020). ClinicalTrials.gov, Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme, (2008). https://clinicaltrials.gov/ct2/show/NCT00731731 (accessed December 10, 2020). ClinicalTrials.gov, Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma, (2010). https://clinicaltrials.gov/ct2/show/NCT01266031 (accessed December 10, 2020). ClinicalTrials.gov, Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma, (2010). https://clinicaltrials.gov/ct2/show/NCT01236560 (accessed December 10, 2020). ClinicalTrials.gov, LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma, (2009). https://clinicaltrials.gov/ct2/show/NCT00859222 (accessed December 10, 2020). ClinicalTrials.gov, A Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas, (2018). https://clinicaltrials.gov/ct2/show/NCT03632317 (accessed December 10, 2020). ClinicalTrials.gov, Panobinostat and Stereotactic Radiation Therapy in Treating Patients With Brain Tumors, (2011). https://clinicaltrials.gov/ct2/show/NCT01324635 (accessed December 10, 2020). ClinicalTrials.gov, FR901228 in Treating Patients With Recurrent High-Grade Gliomas, (2004). https://clinicaltrials.gov/ct2/show/NCT00085540 (accessed December 10, 2020). ClinicalTrials.gov, Valproic Acid With Temozolomide and Radiation Therapy to Treat Brain Tumors, (2006). https://clinicaltrials.gov/ct2/show/NCT00302159 (accessed December 6, 2020). ClinicalTrials.gov, Autologuos Lymphoid Effector Cells Specific Against Tumour (ALECSAT) as Add on to Standard of Care in Patients With Glioblastoma, (2016). https://clinicaltrials.gov/ct2/show/NCT02799238 (accessed December 10, 2020). ClinicalTrials.gov, Comparison of Different Methods to Test MGMT Status in Glioblastoma Patients, (2011). https://clinicaltrials.gov/ct2/show/study/NCT01345370 (accessed December 10, 2020). Cloughesy, 2020, A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE), Neuro. Oncol., 22, 705, 10.1093/neuonc/noz232 ClinicalTrials.gov, GAPVAC Phase I Trial in Newly Diagnosed Glioblastoma Patients, (2014). https://clinicaltrials.gov/ct2/show/NCT02149225 (accessed December 10, 2020). ClinicalTrials.gov, Neo-adjuvant Treatment With Temozolomide and Bevacizumab Previous to Temozolomide Plus Radiation Plus Bevacizumab Therapy in Unresectable Glioblastoma, (2010). https://clinicaltrials.gov/ct2/show/NCT01102595 (accessed December 10, 2020). ClinicalTrials.gov, Preoperative Chemoradiation for Glioblastoma, (2014). https://clinicaltrials.gov/ct2/show/NCT02092038 (accessed December 10, 2020). ClinicalTrials.gov, A Study of Subcutaneous Bevacizumab in Relapsed / Progressive Glioblastoma, (2014). https://clinicaltrials.gov/ct2/show/NCT02157103 (accessed December 10, 2020). ClinicalTrials.gov, Study of Sunitinib Before and During Radiotherapy in Newly Diagnosed Biopsy-only Glioblastoma Patients, (2010). https://clinicaltrials.gov/ct2/show/NCT01100177 (accessed December 10, 2020). Reddy, 2012, Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme, Int. J. Radiat. Oncol. Biol. Phys., 84, 655, 10.1016/j.ijrobp.2012.01.035 ClinicalTrials.gov, Hypofractionated Intensity-Modulated Radiation Therapy With Temozolomide and Bevacizumab for Glioblastoma Multiforme, (2010). https://clinicaltrials.gov/ct2/show/NCT01209442 (accessed December 10, 2020). ClinicalTrials.gov, Nimotuzumab Plus Radiotherapy With Concomitant and Adjuvant Temozolomide for Cerebral Glioblastoma, (2018). https://clinicaltrials.gov/ct2/show/NCT03388372 (accessed December 10, 2020). ClinicalTrials.gov, Ketogenic Diet for Recurrent Glioblastoma, (2007). https://clinicaltrials.gov/ct2/show/NCT00575146 (accessed December 10, 2020). ClinicalTrials.gov, Vandetanib and Sirolimus in Patients With Recurrent Glioblastoma, (2009). https://clinicaltrials.gov/ct2/show/NCT00821080 (accessed December 10, 2020). ClinicalTrials.gov, Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma, (2013). https://clinicaltrials.gov/ct2/show/NCT02014844 (accessed December 10, 2020). ClinicalTrials.gov, Study of LY2228820 With Radiotherapy Plus Concomitant TMZ in the Treatment of Newly Diagnosed Glioblastoma, (2015). https://clinicaltrials.gov/ct2/show/NCT02364206 (accessed December 10, 2020). ClinicalTrials.gov, Phase 0 Analysis of Ixazomib (MLN9708) in Patients With Glioblastoma, (2015). https://clinicaltrials.gov/ct2/show/NCT02630030 (accessed December 10, 2020). ClinicalTrials.gov, Tivozanib for Recurrent Glioblastoma, (2013). https://clinicaltrials.gov/ct2/show/NCT01846871 (accessed December 10, 2020). ClinicalTrials.gov, Tolerance and Pharmacokinetic Study of Chlorogenic Acid to Advanced Glioblastoma, (2016). https://clinicaltrials.gov/ct2/show/NCT02728349 (accessed December 10, 2020). Hazane-Puch, 2016, Sodium selenite decreased HDAC activity, cell proliferation and induced apoptosis in three human glioblastoma cells, Anticancer Agents Med. Chem., 16, 490, 10.2174/1871520615666150819095426 Pei, 2016, HDAC and PI3K antagonists cooperate to inhibit growth of MYC-Driven medulloblastoma, Cancer Cell, 29, 311, 10.1016/j.ccell.2016.02.011 Xu, 2014, Cytostatic and apoptotic effects of DNMT and HDAC inhibitors in endometrial cancer cells, Curr. Pharm. Des., 20, 1881, 10.2174/13816128113199990527 Pathania, 2016, Combined inhibition of DNMT and HDAC blocks the tumorigenicity of cancer Stem-like cells and attenuates mammary tumor growth, Cancer Res., 76, 3224, 10.1158/0008-5472.CAN-15-2249 Krauze, 2015, A phase 2 study of concurrent radiation therapy, temozolomide, and the histone deacetylase inhibitor valproic acid for patients with glioblastoma, Int. J. Radiat. Oncol. Biol. Phys., 92, 986, 10.1016/j.ijrobp.2015.04.038 Lee, 2012, Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: north American Brain Tumor Consortium Study 04-03, Clin. Cancer Res. an Off. J. Am. Assoc. Cancer Res., 18, 6032, 10.1158/1078-0432.CCR-12-1841 Kim, 2017, Phase I/II trial of combination of temozolomide chemotherapy and immunotherapy with fusions of dendritic and glioma cells in patients with glioblastoma, Neurosurgery, 81, N11, 10.1093/neuros/nyx263 Hummel, 2013, A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children’s Oncology Group phase 1 consortium study, Pediatr. Blood Cancer, 60, 1452, 10.1002/pbc.24541 Galanis, 2009, Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol., 27, 2052, 10.1200/JCO.2008.19.0694 Lee, 2015, Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma, Neuro. Oncol., 17, 862, 10.1093/neuonc/nou350 Issa, 2004, Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2’-deoxycytidine (decitabine) in hematopoietic malignancies, Blood, 103, 1635, 10.1182/blood-2003-03-0687 Peereboom, 2010, Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme, J. Neurooncol., 98, 93, 10.1007/s11060-009-0067-2 Chiocca, 2011, Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol., 29, 3611, 10.1200/JCO.2011.35.5222 Wheeler, 2016, Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma, Neuro. Oncol., 18, 1137, 10.1093/neuonc/now002 Gallagher, 2017, Epigenetic modulation in cancer immunotherapy, Curr. Opin. Pharmacol., 35, 48, 10.1016/j.coph.2017.05.006 Bhat, 2018, Immunotherapy With Human Gamma Delta T Cells-Synergistic Potential of Epigenetic Drugs?, Front. Immunol., 9, 512, 10.3389/fimmu.2018.00512 Maio, 2015, Molecular Pathways: At the Crossroads of Cancer Epigenetics and Immunotherapy, Clin. Cancer Res. an Off. J. Am. Assoc. Cancer Res., 21, 4040, 10.1158/1078-0432.CCR-14-2914 Suvà, 2009, EZH2 is essential for glioblastoma cancer stem cell maintenance, Cancer Res., 69, 9211, 10.1158/0008-5472.CAN-09-1622 Shih, 2012, The role of mutations in epigenetic regulators in myeloid malignancies, Nat. Rev. Cancer, 12, 599, 10.1038/nrc3343 Lee, 2012, EZH2 generates a methyl degron that is recognized by the DCAF1/DDB1/CUL4 E3 ubiquitin ligase complex, Mol. Cell, 48, 572, 10.1016/j.molcel.2012.09.004 Tsai, 2010, Long noncoding RNA as modular scaffold of histone modification complexes, Science, 329, 689, 10.1126/science.1192002 Kaneko, 2010, Phosphorylation of the PRC2 component Ezh2 is cell cycle-regulated and up-regulates its binding to ncRNA, Genes Dev., 24, 2615, 10.1101/gad.1983810 Kogo, 2011, Long noncoding RNA HOTAIR regulates polycomb-dependent chromatin modification and is associated with poor prognosis in colorectal cancers, Cancer Res., 71, 6320, 10.1158/0008-5472.CAN-11-1021 Yang, 2011, Long noncoding RNA high expression in hepatocellular carcinoma facilitates tumor growth through enhancer of zeste homolog 2 in humans, Hepatology, 54, 1679, 10.1002/hep.24563 Parsons, 2008, An integrated genomic analysis of human glioblastoma multiforme, Science, 321, 1807, 10.1126/science.1164382 McCabe, 2012, EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations, Nature, 492, 108, 10.1038/nature11606 Knutson, 2012, A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells, Nat. Chem. Biol., 8, 890, 10.1038/nchembio.1084 Varambally, 2008, Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer, Science, 322, 1695, 10.1126/science.1165395 Smits, 2010, miR-101 is down-regulated in glioblastoma resulting in EZH2-induced proliferation, migration, and angiogenesis, Oncotarget, 1, 710, 10.18632/oncotarget.205 Baek, 2016, Gene transfection for stem cell therapy, Curr. Stem Cell Reports., 2, 52, 10.1007/s40778-016-0029-5 O’Duibhir, 2017, Accelerating glioblastoma drug discovery: convergence of patient-derived models, genome editing and phenotypic screening, Mol. Cell. Neurosci., 80, 198, 10.1016/j.mcn.2016.11.001 Urnov, 2010, Genome editing with engineered zinc finger nucleases, Nat. Rev. Genet., 11, 636, 10.1038/nrg2842 Adair, 2017, Hematopoietic stem cell approaches to cancer, Hematol. Oncol. Clin. North Am., 31, 897, 10.1016/j.hoc.2017.06.012 ClinicalTrials.gov, High-Dose Vorinostat and Fractionated Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Glioma, (2011). https://clinicaltrials.gov/ct2/show/NCT01378481 (accessed December 6, 2020). Carén, 2013, The good, the bad and the ugly: epigenetic mechanisms in glioblastoma, Mol. Aspects Med., 34, 849, 10.1016/j.mam.2012.06.007 Harilal, 2020, Revisiting the blood-brain barrier: a hard nut to crack in the transportation of drug molecules, Brain Res. Bull., 160, 121, 10.1016/j.brainresbull.2020.03.018 Linnet, 2008, A review on the impact of P-glycoprotein on the penetration of drugs into the brain. Focus on psychotropic drugs, Eur. Neuropsychopharmacol. J. Eur. Coll. Neuropsychopharmacol., 18, 157, 10.1016/j.euroneuro.2007.06.003